RxDoctor Payments Data

Jessica Petty, DO

Pulmonary Disease · Corona, CANPI 1447631627

Payments from drug & device makers

$5,313in general payments, 2019–2025

Across 65 payments — averaging $81.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • GSK$265
  • Inspire Medical Systems, Inc.$260
  • Baxter Healthcare$139
  • Actelion Pharmaceuticals US, Inc.$125
  • AstraZeneca$124
  • plus $623 from 16 others

What the payments were for

  • Travel & lodging$53710%
  • Food & beverage$1,71832%
  • Education$3,05758%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,313 in reported general payments places this provider in the 65th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$35,875
Medicare patients
174
Services billed
331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter276$302,826
OfevNintedanib Esylate11$142,098
Stiolto RespimatTiotropium Br/Olodaterol Hcl93$82,168
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr90$79,569
Spiriva RespimatTiotropium Bromide90$77,456
Spiriva HandihalerTiotropium Bromide37$32,366
Bevespi AerosphereGlycopyrrolate/Formoterol Fum45$24,373
Fluticasone-SalmeterolFluticasone Propion/Salmeterol94$23,092
Breo ElliptaFluticasone/Vilanterol30$18,803
Albuterol Sulfate HfaAlbuterol Sulfate383$18,618
Advair HfaFluticasone Propion/Salmeterol35$18,100
Wixela InhubFluticasone Propion/Salmeterol54$16,374
DuleraMometasone/Formoterol29$16,074
EliquisApixaban22$15,111
SymbicortBudesonide/Formoterol Fumarate22$9,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$265$401,197396 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$63$301,722194 claims
AstraZenecaBevespi Aerosphere, Symbicort$124$33,47767 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →